Abstract
26. Jordan SC, Vo AA, Peng A et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients [see comment]. Am J Transplant 2006; 6: 459–466 27. Haas M, Montgomery RA, Segev DL et al. Sub-clinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576–585 28. Warren DS, Simpkins CE, Cooper M et al. Modulating Alloimmune responses with plasmapheresis and IVIG. Curr Drug Target Cardiovasc Hematol Disord 2005; 5: 214–222 29. Montgomery Robert A, Zachary Andrea A. Transplanting patients with a positive donor-specific crossmatch: a single center’s perspective. Pediatr Transplant 2004; 8: 535–542 30. Jordan Stanley C, Pescovitz Mark D. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006; 1: 421– 432 31. Stegall MD, Gloor J, Winters JL et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346–351 32. Zachary Andrea A, Montgomery Robert A, Leffell Mary S. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 2005; 66: 364–370 33. Zou y, Stastny P, Susal C et al. Antibodies against MICA antigens and kidney transplant rejection. N Eng J Med 2007; 357: 1293–1300 34. Mizutani K, Terasaki P, Bignon JD et al. Association of kidney transplant failure and antibodies against MICA. Hum Immunol 2006; 67: 683–691 35. Leffell Mary S, Montgomery Robert A, Zachary Andrea A. The changing role of antibody testing in transplantation. Clin Transpl 2005; 259–271
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call